These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

195 related items for PubMed ID: 19372189

  • 1. SELDI-TOF mass spectrometry evaluation of variant transthyretins for diagnosis and pathogenesis of familial amyloidotic polyneuropathy.
    Ueda M, Misumi Y, Mizuguchi M, Nakamura M, Yamashita T, Sekijima Y, Ota K, Shinriki S, Jono H, Ikeda S, Suhr OB, Ando Y.
    Clin Chem; 2009 Jun; 55(6):1223-7. PubMed ID: 19372189
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Effect of albumin on transthyretin and amyloidogenic transthyretin Val30Met disposition and tissue deposition in familial amyloidotic polyneuropathy.
    Taguchi K, Jono H, Kugimiya-Taguchi T, Nagao S, Su Y, Yamasaki K, Mizuguchi M, Maruyama T, Ando Y, Otagiri M.
    Life Sci; 2013 Dec 18; 93(25-26):1017-22. PubMed ID: 24211615
    [Abstract] [Full Text] [Related]

  • 4. Usefulness of MALDI/TOF mass spectrometry of immunoprecipitated serum variant transthyretin in the diagnosis of familial amyloid polyneuropathy.
    Tachibana N, Tokuda T, Yoshida K, Taketomi T, Nakazato M, Li YF, Masuda Y, Ikeda S.
    Amyloid; 1999 Dec 18; 6(4):282-8. PubMed ID: 10611950
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Presence of autoantibody against ATTR Val30Met after sequential liver transplantation.
    Ando Y, Terazaki H, Haraoka K, Tajiri T, Nakamura M, Obayashi K, Misumi S, Shoji S, Hata K, Nakagawa K, Ishizaki T, Uemoto S, Inomata Y, Tanaka K, Okabe H.
    Transplantation; 2002 Mar 15; 73(5):751-5. PubMed ID: 11907422
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. A transgenic rat with the human ATTR V30M: a novel tool for analyses of ATTR metabolisms.
    Ueda M, Ando Y, Hakamata Y, Nakamura M, Yamashita T, Obayashi K, Himeno S, Inoue S, Sato Y, Kaneko T, Takamune N, Misumi S, Shoji S, Uchino M, Kobayashi E.
    Biochem Biophys Res Commun; 2007 Jan 12; 352(2):299-304. PubMed ID: 17126291
    [Abstract] [Full Text] [Related]

  • 10. A novel compound heterozygote (FAP ATTR Arg104His/ATTR Val30Met) with high serum transthyretin (TTR) and retinol binding protein (RBP) levels.
    Terazaki H, Ando Y, Misumi S, Nakamura M, Ando E, Matsunaga N, Shoji S, Okuyama M, Ideta H, Nakagawa K, Ishizaki T, Ando M, Saraiva MJ.
    Biochem Biophys Res Commun; 1999 Oct 22; 264(2):365-70. PubMed ID: 10529370
    [Abstract] [Full Text] [Related]

  • 11. Evidence of the presence of amyloid substance in the blood of familial amyloidotic polyneuropathy patients with ATTR Val30Met mutation.
    Liu J, Lan J, Zhao P, Zheng F, Song J, Zhang P, Sun X.
    Int J Clin Exp Pathol; 2014 Oct 22; 7(11):7795-800. PubMed ID: 25550818
    [Abstract] [Full Text] [Related]

  • 12. Impact of antibodies against amyloidogenic transthyretin (ATTR) on phenotypes of patients with familial amyloidotic polyneuropathy (FAP) ATTR Valine30Methionine.
    Obayashi K, Tasaki M, Jono H, Ueda M, Shinriki S, Misumi Y, Yamashita T, Oshima T, Nakamura T, Ikemizu S, Anan I, Suhr O, Ando Y.
    Clin Chim Acta; 2013 Apr 18; 419():127-31. PubMed ID: 23462670
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Antibody therapy for familial amyloidotic polyneuropathy.
    Su Y, Jono H, Torikai M, Hosoi A, Soejima K, Guo J, Tasaki M, Misumi Y, Ueda M, Shinriki S, Shono M, Obayashi K, Nakashima T, Sugawara K, Ando Y.
    Amyloid; 2012 Jun 18; 19 Suppl 1():45-6. PubMed ID: 22506915
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Pathogenesis and therapy for transthyretin related amyloidosis].
    Ando Y, Jono H.
    Rinsho Byori; 2008 Feb 18; 56(2):114-20. PubMed ID: 18402051
    [Abstract] [Full Text] [Related]

  • 18. Characterization of transthyretin variants in familial transthyretin amyloidosis by mass spectrometric peptide mapping and DNA sequence analysis.
    Lim A, Prokaeva T, McComb ME, O'Connor PB, Théberge R, Connors LH, Skinner M, Costello CE.
    Anal Chem; 2002 Feb 15; 74(4):741-51. PubMed ID: 11866053
    [Abstract] [Full Text] [Related]

  • 19. A non-invasive method based on saliva to characterize transthyretin in familial amyloidotic polyneuropathy patients using FT-ICR high-resolution MS.
    da Costa G, Guerreiro A, Correia CF, Gomes RJ, Freire A, Monteiro E, Barroso E, Coelho AV, Outeiro TF, Freire AP, Cordeiro C.
    Proteomics Clin Appl; 2010 Jul 15; 4(6-7):674-8. PubMed ID: 21179887
    [Abstract] [Full Text] [Related]

  • 20. A chemometric approach for characterization of serum transthyretin in familial amyloidotic polyneuropathy type I (FAP-I) by electrospray ionization-ion mobility mass spectrometry.
    Pont L, Sanz-Nebot V, Vilaseca M, Jaumot J, Tauler R, Benavente F.
    Talanta; 2018 May 01; 181():87-94. PubMed ID: 29426546
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.